Utility of ProGRP determinations in cancer patients.

Abstract

BACKGROUND:

The aim of this study was to assess the utility of ProGRP determinations in patients with selected cancer localization, during and after therapy.

MATERIALS AND METHODS:

The study involved a reference group and a population of lung, breast, ovarian, and prostate cancer patients. ProGRP was evaluated using two-step chemiluminescent microparticle immunoassay (CMIA) manufactured by Abbott Diagnostics, and Architect i2000 analyzer.

RESULTS:

During follow-up of SCLC patients, an increased value for ProGRP was found in 51% and for NSE only in 25.5% of the patients, whereas in NSCLC patients, percentages with elevated ProGRP and CYFRA 21-1 were 8.6% and 55.7%, respectively. SCLC patients also had the highest AUC values for ProGRP. In other cancers, the frequency of elevated ProGRP results were as follows: 13.1%--in breast cancer patients, 19.6%--in ovarian cancer patients, and 15.1%--in prostate cancer patients.

CONCLUSIONS:

The presented study revealed that ProGRP is a tumor marker of choice in SCLC, because of its high diagnostic specificity in relation to the reference group and to the group with other malignancies.

• Authors: Ewa Wojcik, Urszula Rychlik, Piotr Skotnicki, Jerzy Jakubowicz, Jan Kanty Kulpa
• Journal: Clinical laboratory (Clin Lab) Vol. 56 Issue 11-12 Pg. 527-34 ( 2010) ISSN: 1433-6510 [Print] Germany
• PMID: 21141436 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• Peptide Fragments
• Recombinant Proteins
• pro-gastrin-releasing peptide (31-98)
• Phosphopyruvate Hydratase

Topics

• Adult
• Aged
• Biomarkers, Tumor (blood)
• Female
• Humans
• Immunoassay
• Luminescent Measurements
• Male
• Middle Aged
• Neoplasms (blood)
• Peptide Fragments (blood)
• Phosphopyruvate Hydratase (blood)
• ROC Curve
• Recombinant Proteins (blood)
• Reference Values